Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist 2020-10-12 08:30
Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist 2020-09-14 08:30
Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist) 2020-09-09 18:30
Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen 2020-08-20 20:00
First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody 2020-08-17 08:30
Ascletis' All-oral HCV Treatment Approved for Marketing in China 2020-07-31 08:47
Bridging Study in China Completed for NASH Drug Candidate ASC40 2020-07-20 08:30
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial 2020-06-17 20:30
Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication 2020-05-13 18:30
Ascletis Receives IND Approval for its HIV Drug ASC09F 2020-04-13 20:00
Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020 2020-04-01 08:30
Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients 2020-03-25 08:28
Progress of the Small Sample Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia 2020-03-10 17:30
Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia 2020-02-27 08:00
Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA 2020-02-18 08:00
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody 2020-01-23 09:52
Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout 2019-11-29 08:00
Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer 2019-10-08 08:00
Ascletis Announces Departure of Chief Financial Officer 2019-09-30 16:30
Ascletis Announces Departure of Chief Financial Officer 2019-09-30 16:30
1 4 5 6 7 8